Abstract
Infection with the Human Papilloma Virus (HPV) is extremely common worldwide. Persistent infection with high-risk strains can lead to genital tract premalignant and malignant lesions. Two licensed prophylactic HPV vaccines against cervical malignancy are commercially available. In naive patients both vaccines showed close to 100% efficacy against persistent infection and genital disease associated with the vaccine-targeted HPV types, as well as excellent safety over several years of study. Here we present a discussion on the appropriate age and gender in which to propose vaccination, and conclude that the most suitable recommendation is for vaccination of adolescents.
| Original language | English |
|---|---|
| Pages (from-to) | 2-5 |
| Number of pages | 4 |
| Journal | Pediatric Endocrinology Reviews |
| Volume | 8 |
| Issue number | 1 |
| State | Published - Sep 2010 |
Keywords
- Cervical cancer
- Genital warts
- HPV vaccine
- Human papillomavirus
- Sexual debut
